Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases

Background and Objectives Few studies have addressed the optimal duration of chemotherapy, particularly prior to liver resection for colorectal liver metastases (CLM). The purpose of this retrospective analysis was to evaluate time to maximal response in patients receiving systemic ± hepatic arteria...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2008-06, Vol.97 (7), p.601-604
Main Authors: White, Rebekah R., Schwartz, Lawrence H., Munoz, Jose A., Raggio, Greer, Jarnagin, William R., Fong, Yuman, D'Angelica, Michael I., Kemeny, Nancy E.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
chemotherapy
colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Dexamethasone - administration & dosage
Female
Floxuridine - administration & dosage
Fluorouracil - administration & dosage
Humans
Infusions, Intra-Arterial
Leucovorin - administration & dosage
liver metastasis
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Male
Middle Aged
Organoplatinum Compounds - administration & dosage
regional therapy
Retrospective Studies
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objectives Few studies have addressed the optimal duration of chemotherapy, particularly prior to liver resection for colorectal liver metastases (CLM). The purpose of this retrospective analysis was to evaluate time to maximal response in patients receiving systemic ± hepatic arterial infusion (HAI) chemotherapy alone for the treatment of CLM. Methods We reviewed 35 patients with CLM on clinical trials of HAI floxuridine/dexamethasone plus systemic oxaliplatin with 5‐fluorouracil/leucovorin or irinotecan (PUMP + SYSTEMIC). We retrospectively identified 35 patients with CLM who received first‐line systemic 5FU/leucovorin/oxaliplatin (FOLFOX) ± bevacizumab (SYSTEMIC) during the same time period. Measurable disease was evaluated on CT scans performed at 2‐month intervals. The sum of the products of bi‐dimensional tumor measurements for representative lesions was compared both to baseline imaging and between consecutive time points. Results In responders to therapy, mean cumulative tumor reduction increased from 61% at 2 months to 73% at 4 months in the PUMP + SYSTEMIC group (P 
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.21042